Navigation Links
Dendreon Reports First Quarter 2009 Financial Results
Date:5/6/2009

  • Presented data from the PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11 Phase 3 study suggesting that PROVENGE induces long-term memory immune responses that are durable and can be maintained following boosting. The results of the study also indicate that CD54 upregulation on Antigen Presenting Cells (APC), a measure of product potency, is a correlate of immune activation. P-11 is an ongoing Phase 3 clinical trial designed to evaluate the safety and biologic activity of PROVENGE in patients with non-metastatic androgen-dependent (hormone sensitive) prostate cancer who have had a prostate-specific antigen (PSA) recurrence following surgical removal of the prostate.

  • "The significant increase in overall survival demonstrated in our Phase 3 IMPACT trial for PROVENGE is a major milestone for the company and puts us one step closer to making PROVENGE available to patients with prostate cancer who currently have few appealing treatment options," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We look forward to reviewing our commercialization plans for PROVENGE in more detail during a webcast analyst day this summer."

    In lieu of a conference call, the Company will present at several upcoming investor conferences that will be webcast, three of which are later this month and include:

    • Bank of America / Merrill Lynch 2009 Health Care Conference on May 12, 2009
    • Deutsche Bank 34th Annual Healthcare Conference on May 19, 2009
    • Leerink Swann Novel Cancer Therapeutics: Roundtable Conference on May 20, 2009

    About Dendreon

    Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel th
    '/>"/>

    SOURCE Dendreon Corporation
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
    2. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
    3. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
    4. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
    5. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
    6. Dendreon Reports Third Quarter 2008 Financial Results
    7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
    8. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
    9. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
    10. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
    11. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... 2, 2015 Biovista Inc. is ... the 2015 BeHEARD science challenge, a global competition hosted ... researchers, access to the latest life science innovations and ... and pathway analytics capability to support Steven Laffoon ... the study of Niemann-Pick Disease Type A (NPA), a ...
    (Date:9/2/2015)... SAN FRANCISCO, Calif. , Sept. 2, 2015 /PRNewswire/ ... that Bonnie H. Anderson , president and chief ... Healthcare Conference on Wednesday, September 16, 2015 at 10:30 ... . The live audio webcast and ... http://investor.veracyte.com . The webcast will be available shortly after ...
    (Date:9/2/2015)... ... September 02, 2015 , ... Whitehouse Laboratories ... be attending Pharma Ed Resources upcoming educational seminar and training session on Extractable ... this timely conference will provide Updates & Case Studies on the Latest Compliance ...
    (Date:9/1/2015)... ... September 02, 2015 , ... Spirax Sarco , the leader in products ... Spirax Sarco Anytime. This platform, offering unique online ordering capabilities, is only available ... Log on to Spirax Sarco Anytime and within minutes you can be making ...
    Breaking Biology Technology:Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Spirax Sarco Announces New Features to Anytime Platform 2
    ... LMNX ) announced today that it has joined ... Match to raise awareness of the need for additional donors ... growing number of patients awaiting life-saving bone marrow transplants.  Recently, ... Registry in an effort to assist patients nationwide. Luminex will ...
    ... Oct. 5, 2011 SRI International has been awarded ... $14.3 million. The contracts provide SRI up to $11.7 ... for pharmacology and pharmacokinetics studies that will be carried ... These five-year contracts extend SRI,s preclinical studies for the ...
    ... Oct. 5, 2011 Adeona Pharmaceuticals, Inc. (NYSE Amex: ... central nervous system diseases, announced today that James S. Kuo, ... provide a brief update on its Alzheimer,s program at the ... companies at the invitation-only event on Tuesday evening, October 11, ...
    Cached Biology Technology:Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match® 2Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match® 3Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match® 4SRI International Awarded Two National Cancer Institute Preclinical Development Service Contracts 2SRI International Awarded Two National Cancer Institute Preclinical Development Service Contracts 3Adeona CEO to Present at the NYC Medtech Forum 2
    (Date:8/25/2015)... CITY and BELLEVUE, Wash. ... leader in advanced robotic systems, announced today it will ... unmanned ground vehicle (UGV), at the National Tactical Officers ... The Guardian S is the first-ever ... culmination of years of research and in-field trials and ...
    (Date:8/20/2015)... , Aug. 20, 2015 The ... consumers that are active and healthy. However, wearable ... the hospital environment to help improve diagnostic capabilities ... video from the Wearable Technologies Conference 2015 ... new applications for wearables in healthcare.    ...
    (Date:8/19/2015)... N.Y. , Aug. 19, 2015  VOXX ... that it has entered into a Definitive Agreement ... property, of iris authentication market leader EyeLock through ... VOXX will have a controlling interest in the ... subject to completion of due diligence.  Expanding on ...
    Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
    ... Center has opened a new clinical study using a ... glioblastoma multiforme, a largely untreatable brain tumor. This ... in patients using measles to kill cancer. , "We ... the most lethal cancers," says Eva Galanis, M.D., oncologist ...
    ... thought to act as an oxygen store in the heart ... exists in many other tissues of the common carp, enabling ... Myglobin is found in large quantities in diving mammals such ... long periods during deep sea dives. Similarly in humans, myglobin ...
    ... targeted therapy with a common anti-inflammatory produced promising ... at UCLA's Jonsson Cancer Center reported. , Pairing ... Celebrex increased response rates in lung cancer patients ... assistant professor of hematology/oncology and lead author of ...
    Cached Biology News:Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer 2Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer 3Common carp sheds new light on surviving in extreme environments 2Combination therapy shows promising results in patients with advanced lung cancer 2Combination therapy shows promising results in patients with advanced lung cancer 3
    ... ISO 9001:2000 Certified USDA Research Registered ... SOP's Training AALAS Certified Technicians ... Procedures GLP Documentation Upon Request Focus ... point for all your custom immunology service ...
    Human IL-17D Affinity Purified Polyclonal Ab...
    BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
    ... Clone/PAD: ZMD.414. Immunogen: Synthetic peptide ... mouse and rat mTOR (Mammalian target of ... for the human mTOR protein. On ... at ~235 kDa. Reactivity: Human (positive ...
    Biology Products: